10301 Stella Link Rd, Suite C | Houston, TX 77025 832.538.1600 | 888.482.5327

Better patient care
starts before
the prescription.

CompanionDx™ assesses genetic variations in patients to help physicians create optimized drug treatment plans.

Startlingly, today’s figures show that anywhere between 40 and 75 percent of drugs are ineffective for individual patients depending on drug class. That means a large portion of patients may not only be wasting their money—but they may not be receiving the treatment they’re seeking or the results they desire.

CompanionDx™ is working to turn these figures around. Through pharmacogenomics, we aid physicians in understanding the genetic information of each individual patient, so doctors can offer the most effective diagnoses and treatment plans. From understanding individual metabolism to assessing drug sensitivities, CompanionDx™ offers a personalized approach to drug therapy—for more effective therapeutic regimens.

View sample report

Benefits of choosing CompanionDx™ for pharmacogenomics testing include:

  • Higher quality healthcare
  • Safer, more efficient and effective therapy
  • Increased accuracy and fail-safe sampling in identifying drug sensitivity levels
  • Results in 3-7 days
  • Doctor-approved guidelines for incorporating actionable information into routines for patient care

CompanionDx™ performs Personalized Pharmacogenomics Evaluations (PPE) for the following biomarkers:

  • CYP450 2C19
    Click here to access related drug treatments
  • CYP450 2C9 
    Click here to access related drug treatments
  • CYP450 2D6 
    Click here to access related drug treatments
  • CYP450 3A4 
    Click here to access related drug treatments
  • CYP450 3A5 
    Click here to access related drug treatments

CompanionDx™ offers the Thrombophilia Risk Test (TRT) for the following biomarkers:

  • Factor II
  • Factor V
  • MTHFR (Methylenetetrahydrofolate reductase)
    Click here to access related drug treatments

CompanionDx™ performs the following drug sensitivity tests:

  • Tamoxifen (based on CYP450 2D6 gene)
  • 5-Fluorouracil (based on MTHFR mutation)
Follow us on Twitter Like us on Facebook